- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Azitra, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 3 | SEC Filings | ||
| 17.12.25 | Azitra receives NYSE American approval of listing compliance plan | 1 | Seeking Alpha | ||
| 17.12.25 | Azitra receives approval for NYSE American compliance plan | 3 | Investing.com | ||
| 17.12.25 | Azitra, Inc.: Azitra Receives Notice of Acceptance of the Listing Standards Compliance Plan from NYSE American | 133 | PR Newswire | BRANFORD, Conn., Dec. 17, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies... ► Artikel lesen | |
| AZITRA Aktie jetzt für 0€ handeln | |||||
| 17.12.25 | Azitra, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 10.12.25 | Azitra, Inc. - S-1, General form for registration of securities | - | SEC Filings | ||
| 01.12.25 | Azitra, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 25.11.25 | Azitra, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 24.11.25 | Azitra announces $1.5 million private placement at premium to market | 1 | Investing.com | ||
| 13.11.25 | Azitra reports Q3 results | 1 | Seeking Alpha | ||
| 12.11.25 | Azitra, Inc. Announces Q3 2025 Results and Provides Business Updates | 146 | PR Newswire | BRANFORD, Conn., Nov. 12, 2025 /PRNewswire/ -- Azitra, Inc. ("Azitra") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative... ► Artikel lesen | |
| 12.11.25 | Azitra, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 12.11.25 | Azitra, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 07.11.25 | Azitra denies report of $44 million direct offering, stock drops | 11 | Seeking Alpha | ||
| 07.11.25 | Azitra denies false report of $44 million registered direct offering | 2 | Investing.com | ||
| 07.11.25 | Azitra, Inc. Addresses False Report Regarding Sale of Securities | 93 | PR Newswire | BRANFORD, Conn., Nov. 7, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies... ► Artikel lesen | |
| 20.10.25 | Azitra stock soars after positive preclinical data for ichthyosis treatment | 2 | Investing.com | ||
| 20.10.25 | Azitra-Aktie schießt nach positiven präklinischen Daten für Hauttherapie in die Höhe | 5 | Investing.com Deutsch | ||
| 20.10.25 | Azitra, Inc. Announces Positive Preclinical Data for ATR-01 Program, Designed to Treat Ichthyosis Vulgaris | 191 | PR Newswire | ATR-01, which uses a filaggrin-secreting strain of S. epidermidis, is in preclinical development for ichthyosis vulgaris
Preclinical data show production of active... ► Artikel lesen | |
| 03.10.25 | Azitra erhält Non-Compliance-Mitteilung der NYSE American | 1 | Investing.com Deutsch |
1 2 Weiter >>
40 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 44,620 | +0,64 % | Adidas schmiert ab, Qiagen zieht an: DAX-Ausblick | Der DAX hat eine volatile Woche hinter sich. Unter dem Strich büßte das größte deutsche Börsenbarometer knapp 400 Punkte ein und schloss -1,57% tiefer mit 24.900 Punkten. Die höchsten Verluste gab es... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 314,30 | -0,12 % | H.C. Wainwright raises Praxis Precision Medicines stock price target to $1,245 | ||
| NUVALENT | 102,89 | +0,45 % | Royalty Pharma plc: Royalty Pharma Acquires Royalty Interest in Nuvalent's Neladalkib and Zidesamtinib for Up to $315 Million | NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a pre-existing royalty interest in Nuvalent's neladalkib and zidesamtinib from an... ► Artikel lesen | |
| NURIX THERAPEUTICS | 16,520 | -6,03 % | Nurix Therapeutics, Inc.: Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides a Corporate Update | First patients dosed in DAYBreak registrational program for bexobrutideg in relapsed/refractory CLLPresented Phase 1 results at ASH 2025 that support bexobrutideg's potential best-in-class profile... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 14,290 | -3,77 % | Gubra A/S: Amylyx Pharmaceuticals Announces Nomination of AMX0318 as a Novel, Long-Acting GLP-1 Receptor Antagonist Development Candidate, Identified in Collaboration with Gubra | AMX0318 selected as development candidate after meeting key criteria, demonstrating a robust chemical stability profile, strong in vitro potency, evidence of in vivo efficacy and tolerability, high... ► Artikel lesen | |
| OLEMA PHARMACEUTICALS | 25,720 | -1,30 % | Olema Pharmaceuticals: Aktie fällt nach angekündigtem CFO-Abgang | ||
| HARMONY BIOSCIENCES | 36,520 | -0,92 % | How Harmony Biosciences Can Prove Its Skeptics Wrong | ||
| APOGEE THERAPEUTICS | 65,42 | -6,52 % | Apogee Therapeutics: Empfehlung liefert +129% in 6 Monaten | Im Juli letzten Jahres präsentierten wir im Rahmen unserer Berichterstattung und innerhalb unserer erfolgreichen Community die Aktie von Apogee Therapeutics als heißen Kauftipp. Grundlage war eine ausgeprägte... ► Artikel lesen | |
| BIONTECH | 95,80 | -0,21 % | Pharma- und Biotech-Aktien 2026: Bayer und BioNTech geben Gas, Bioxyne vor Durchbruch? | ||
| ERASCA | 10,525 | +2,09 % | Guggenheim More Than Doubles Erasca (ERAS) PT Following Clinical Progress and Updated Pipeline Models | ||
| STRUCTURE THERAPEUTICS | 88,44 | +1,48 % | Structure Therapeutics gains on report suggesting it may be a top takeover target | ||
| AVIDITY BIOSCIENCES | 72,58 | +0,03 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| ARVINAS | 13,380 | 0,00 % | Arvinas Inc.: Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson's Disease and Movement Disorders | - ARV-102 was well tolerated in clinical trials for both healthy volunteers and patients with Parkinson's disease - - ARV-102 demonstrated dose-dependent cerebrospinal fluid (CSF) exposure in subjects... ► Artikel lesen | |
| TRAVERE THERAPEUTICS | 31,110 | -2,75 % | Block & Leviton LLP: Travere Therapeutics ALERT: Securities Fraud Investigation by Block & Leviton Could Allow TVTX Investors to Recover Losses | Boston, Massachusetts--(Newsfile Corp. - January 16, 2026) - Block & Leviton is investigating Travere Therapeutics, Inc. (NASDAQ: TVTX) for potential securities law violations. Investors who have... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 14,460 | -6,10 % | Summit Therapeutics: FDA akzeptiert Zulassungsantrag für Lungenkrebsmedikament Ivonescimab |
Das Unternehmen AZITRA INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -9,08 % bei einem Aktienkurs von 0,243 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu AZITRA INC finden Sie auf Wallstreet Online.